Key market opportunities in the shingles vaccine sector include rising elderly populations; expanding healthcare ...

Daiichi Sankyo (TSE:4568) posted 11.8% earnings growth over the last twelve months, trailing its 32.7% average from the past five years. Net profit margin edged down to 14.1% from 14.2% a year ago.

Detailed price information for Daiichi Sankyo Ltd (DSKYF) from The Globe and Mail including charting and trades.

Detailed price information for Daiichi Sankyo Ltd (DSKYF) from The Globe and Mail including charting and trades.

These pivotal studies investigated AstraZeneca and Daiichi Sankyo’s Enhertu, a human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate with a topoisomerase II-targeting ...

Investing.com - Daiichi Sankyo stock fell 4.5% on Friday after the Japanese pharmaceutical company maintained its core operating profit target at ¥350 billion despite strong sales performance.

(Alliance News) - Daiichi Sankyo Co Ltd and AstraZeneca PLC on Friday said they began new phase 3 clinical trial testing of an intravenous treatment for advanced lung cancer.

The decision by the Canadian regulator is supported by the findings from the Phase III DESTINY-Breast06 study.

The ASX biotech sector ran strongly in October, but the big-cap thoroughbreds found the track conditions more challenging.

Daiichi Sankyo Company, Limited ( OTCPK:DSNKY) Discusses ESMO 2025 Highlights With Focus on Key Breast Cancer Trial Data and Regulatory Submissions October 21, 2025 8:00 AM EDT ...

Q3 2025 Earnings Call November 3, 2025 4:30 PM ESTCompany ParticipantsRobert DeVitaDavid Hung - Founder, President, CEO ...

Merck & Co. began Tuesday with back-to-back deals, revealing separate agreements to pay $150 million upfront for full control of an early-phase asset and pocket $700 million to support an expansive ...